In this issue:
Ustekinumab concentrations and PASI response
Secukinumab dosing optimisation
5-year safety of ixekizumab
Gluten intake and risk of psoriasis, PsA and atopic dermatitis
Molecular and cellular responses to a new TYK2/JAK1 inhibitor
Long-term efficacy and safety of brodalumab
Crisaborole 2% for intertriginous, anogenital and facial psoriasis
Clinicopathologic overlap of psoriasis, eczema and psoriasiform dermatoses
Greater cumulative benefits from ixekizumab vs ustekinumab
Mycobacterium tuberculosis infection in psoriatic patients on biologics
Rapid response of biologic treatments in moderate-to-severe plaque psoriasis
Please login below to download this issue (PDF)